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A hematoxylin and eosin (H&E)-stained 
section of a canine lymph node 
showing the At-211 dose rate 
distribution in red/yellow, quantified 
through alpha imaging. The lymph node 
was biopsied and immediately frozen 
two hours after the radioactive injection, 
at which point the accumulation of At-
211 was high in the T cell-rich 
paracortex. 
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Hematopoietic cell transplantation can successfully cure many hematological diseases including 
cancers. The success of this therapy depends on efficiently removing malignant cells, as well as 
suppressing the immune system of the patient. Chemotherapy and whole body gamma irradiation 
are standard conditioning regimens, yet these aggressive approaches have extensive side effects. 
Radiolabeled monoclonal antibodies are being explored as approaches to increase the specificity 
and efficacy for targeting host hematopoietic cells. Monoclonal antibodies (MAbs) targeting the cell 
surface protein CD45 are known to recognize nearly all hematopoietic cells and serve as an 
excellent targeting agent; however, to date studies have mainly paired anti-CD45-expressing MAbs 
with beta-emitting isotopes. Compared to beta emitters, alpha-emitting isotopes release higher-
energy particles with shorter range, which is likely to increase both the specificity and the efficacy of 
the treatment. Dr. Sofia Frost and colleagues from the Clinical Research Division demonstrate the 
feasibility of alpha-radioimmunotherapy in The Journal of Nuclear Medicine. 
The high energy and short range of alpha radiation is ideal for antibody-guided targeted therapies of 
hematological malignancies, however, the limited particle range makes calculation of absorbed 
radiation doses in tissues difficult. In this study, Dr. Frost and investigators overcame this challenge 
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using ex vivo alpha imaging in a canine model. Anti-CD45-expressing MAbs were radiolabeled with 
the alpha emitter astatine-211 (
211
At) and infused into animals. Using alpha imaging and flow 
cytometry of biopsied bone marrow and lymph node samples the researchers demonstrated that this 
targeted approach was comparable to current pre-treatment approaches utilizing whole body gamma 
radiation, “ We are showing that the absorbed doses that are achieved in this model compare well 
with, or exceed, those used in standard external beam total body irradiation regimens” , said Dr. 
Frost. The high spatial resolution of the alpha images makes this techinque sensitive enough to 
efficiently reveal the specificity of 
211
At-conjugated anti-CD45 MAbs. Different regions within lymph 
nodes contain varying amounts of CD45-positive immune cells, and by alpha imaging these were 
clearly distinguished. The T cell-rich paracortex, for instance, was the region that contained the most 
211
At-anti-CD45. Thus the authors conclude that 
211
At-anti-CD45 radioimmunotherapy efficiently 
targets hematopoietic cells for transplant pre-treatment without severe toxicity, and that ex vivo 
alpha imaging enables better prediction and understanding of the therapeutic outcome. 
These initial safety and biodistribution studies will allow for test treatments of canine patients with 
spontaneous lymphoma. Excitingly, human applications are also underway, “ Clinical trials using 
alpha emitters like astatine-211 are currently being developed at Fred Hutch…and we anticipate they 
will open in the next year.”  said Dr. Frost. 
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